Retatrutide 40mg Pen

Retatrutide, also known as LY3437943, is an investigational molecule being studied for its activity at three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. This triple-agonist mechanism has made retatrutide an important subject of metabolic and obesity research.

The Retatrutide 40mg Pen is listed here as a research product. The 40mg product strength is a product-specific specification and should not be confused with the doses evaluated in published clinical trials. The 2023 phase 2 obesity study investigated weekly retatrutide doses of 1mg, 4mg, 8mg and 12mg over 48 weeks.

Research Background

Published research has investigated retatrutide because of its combined GIP, GLP-1 and glucagon receptor activity. In the phase 2 obesity trial published in the New England Journal of Medicine, researchers evaluated several retatrutide dose groups and reported substantial reductions in body weight during the study period. Gastrointestinal adverse events were among the most frequently reported events, and increases in heart rate were also observed.

Retatrutide remains an investigational compound. Current information from its developer states that it has not been approved by a regulatory agency and is being studied in Phase 3 clinical trials.

Product Information

• Compound: Retatrutide
• Alternative identifier: LY3437943
• Product strength: 40mg
• Form: Pen
• Classification: Investigational research compound
• Receptor activity: GIP / GLP-1 / glucagon
• Research area: Metabolic and obesity research

Important: The 40mg product strength should not be represented as a clinical dose or recommended dosing regimen. Published phase 2 research evaluated different dose levels, including up to 12mg.

Synedica Retatrutide 40mg Pen

Scientific References / External Links

These are the external links I recommend adding rather than random commercial links.

Anchor text: current  Retatrutide 40mg Pen research information

Retatrutide Research Information — Lilly

Placement: Research/Regulatory Information section.

These references give the page legitimate topical relevance and support the claims rather than simply adding outbound links for an SEO plugin.

FAQ

What is retatrutide?

Retatrutide (LY3437943) is an investigational molecule that activates GIP, GLP-1 and glucagon receptors. It is being studied in clinical research involving metabolic and obesity-related conditions.

What is Retatrutide 40mg Pen?

It is a pen-form research product identified as containing 40mg of retatrutide. The product-specific strength should not be confused with doses used in clinical trials.

Is retatrutide approved?

Current information from Lilly states that retatrutide has not been approved by any regulatory agency and remains under clinical investigation.

Has retatrutide been studied for obesity?

Yes. A peer-reviewed phase 2 study investigated retatrutide in adults with obesity or overweight with a weight-related condition.

How does  Retatrutide 40mg Pen work?

Retatrutide is designed to activate three receptor pathways: GIP, GLP-1 and glucagon. This differentiates it mechanistically from medicines that target only one or two of these pathways.

What doses were studied in clinical research?

The published phase 2 obesity study evaluated 1mg, 4mg, 8mg and 12mg once-weekly treatment groups.